These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

491 related articles for article (PubMed ID: 26637773)

  • 21. Langerhans cell histiocytosis in children: from the bench to bedside for an updated therapy.
    Aricò M
    Br J Haematol; 2016 Jun; 173(5):663-70. PubMed ID: 26913480
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Frequency of MAP2K1, TP53, and U2AF1 Mutations in BRAF-mutated Langerhans Cell Histiocytosis: Further Characterizing the Genomic Landscape of LCH.
    McGinnis LM; Nybakken G; Ma L; Arber DA
    Am J Surg Pathol; 2018 Jul; 42(7):885-890. PubMed ID: 29649018
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pediatric Langerhans cell histiocytosis: the impact of mutational profile on clinical progression and late sequelae.
    Nann D; Schneckenburger P; Steinhilber J; Metzler G; Beschorner R; Schwarze CP; Lang P; Handgretinger R; Fend F; Ebinger M; Bonzheim I
    Ann Hematol; 2019 Jul; 98(7):1617-1626. PubMed ID: 30923995
    [TBL] [Abstract][Full Text] [Related]  

  • 24. BRAF Mutation Correlates With High-Risk Langerhans Cell Histiocytosis and Increased Resistance to First-Line Therapy.
    Héritier S; Emile JF; Barkaoui MA; Thomas C; Fraitag S; Boudjemaa S; Renaud F; Moreau A; Peuchmaur M; Chassagne-Clément C; Dijoud F; Rigau V; Moshous D; Lambilliotte A; Mazingue F; Kebaili K; Miron J; Jeziorski E; Plat G; Aladjidi N; Ferster A; Pacquement H; Galambrun C; Brugières L; Leverger G; Mansuy L; Paillard C; Deville A; Armari-Alla C; Lutun A; Gillibert-Yvert M; Stephan JL; Cohen-Aubart F; Haroche J; Pellier I; Millot F; Lescoeur B; Gandemer V; Bodemer C; Lacave R; Hélias-Rodzewicz Z; Taly V; Geissmann F; Donadieu J
    J Clin Oncol; 2016 Sep; 34(25):3023-30. PubMed ID: 27382093
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MAPK/ERK signal pathway alterations in patients with Langerhans Cell Histiocytosis.
    Novosad O; Skrypets T; Pastushenko Y; Titorenko I; Martynchyk A; Skachkova O; Inomistova M; Gorbach A; Khranovska N; Kryachok I
    Klin Onkol; 2018; 31(2):130-136. PubMed ID: 29708356
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Erdheim-Chester disease (ECD), an inflammatory myeloid neoplasia].
    Haroche J; Papo M; Cohen-Aubart F; Charlotte F; Maksud P; Grenier PA; Cluzel P; Mathian A; Emile JF; Amoura Z
    Presse Med; 2017 Jan; 46(1):96-106. PubMed ID: 27234902
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MAP2K1 and MAP3K1 mutations in Langerhans cell histiocytosis.
    Nelson DS; van Halteren A; Quispel WT; van den Bos C; Bovée JV; Patel B; Badalian-Very G; van Hummelen P; Ducar M; Lin L; MacConaill LE; Egeler RM; Rollins BJ
    Genes Chromosomes Cancer; 2015 Jun; 54(6):361-8. PubMed ID: 25899310
    [TBL] [Abstract][Full Text] [Related]  

  • 28. BRAFV600E and MAP2K1 mutations in Langerhans cell histiocytosis occur predominantly in children.
    Zeng K; Ohshima K; Liu Y; Zhang W; Wang L; Fan L; Li M; Li X; Wang Z; Guo S; Yan Q; Guo Y
    Hematol Oncol; 2017 Dec; 35(4):845-851. PubMed ID: 27597420
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation.
    Su F; Bradley WD; Wang Q; Yang H; Xu L; Higgins B; Kolinsky K; Packman K; Kim MJ; Trunzer K; Lee RJ; Schostack K; Carter J; Albert T; Germer S; Rosinski J; Martin M; Simcox ME; Lestini B; Heimbrook D; Bollag G
    Cancer Res; 2012 Feb; 72(4):969-78. PubMed ID: 22205714
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hematopoietic origin of Langerhans cell histiocytosis and Erdheim-Chester disease in adults.
    Milne P; Bigley V; Bacon CM; Néel A; McGovern N; Bomken S; Haniffa M; Diamond EL; Durham BH; Visser J; Hunt D; Gunawardena H; Macheta M; McClain KL; Allen C; Abdel-Wahab O; Collin M
    Blood; 2017 Jul; 130(2):167-175. PubMed ID: 28512190
    [TBL] [Abstract][Full Text] [Related]  

  • 31. BRAF and MAP2K1 mutations in Langerhans cell histiocytosis: a study of 50 cases.
    Alayed K; Medeiros LJ; Patel KP; Zuo Z; Li S; Verma S; Galbincea J; Cason RC; Luthra R; Yin CC
    Hum Pathol; 2016 Jun; 52():61-7. PubMed ID: 26980021
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Circulating cell-free BRAF
    Héritier S; Hélias-Rodzewicz Z; Lapillonne H; Terrones N; Garrigou S; Normand C; Barkaoui MA; Miron J; Plat G; Aladjidi N; Pagnier A; Deville A; Gillibert-Yvert M; Moshous D; Lefèvre-Utile A; Lutun A; Paillard C; Thomas C; Jeziorski E; Nizard P; Taly V; Emile JF; Donadieu J
    Br J Haematol; 2017 Aug; 178(3):457-467. PubMed ID: 28444728
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Langerhans cell histiocytosis in adults: Advances in pathophysiology and treatment.
    Kobayashi M; Tojo A
    Cancer Sci; 2018 Dec; 109(12):3707-3713. PubMed ID: 30281871
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dramatic efficacy of dabrafenib in Erdheim-Chester disease (ECD): a pediatric patient with multiple large intracranial ECD lesions hidden by refractory Langerhans cell histiocytosis.
    Hao X; Feng R; Bi Y; Liu Y; Li C; Lu T; Tian Y
    J Neurosurg Pediatr; 2019 Jan; 23(1):48-53. PubMed ID: 30265230
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular and clinicopathologic characterization of pediatric histiocytoses.
    Hélias-Rodzewicz Z; Donadieu J; Terrones N; Barkaoui MA; Lambilliotte A; Moshous D; Thomas C; Azarnoush S; Pasquet M; Mansuy L; Aladjidi N; Jeziorski E; Marec-Berard P; Gilibert-Yvert M; Spiegel A; Saultier P; Pellier I; Pagnier A; Pertuisel S; Poiree M; Bodet D; Millot F; Isfan F; Stephan JL; Leruste A; Rigaud C; Filhon B; Carausu L; Reguerre Y; Kieffer I; Brichard B; Ben Jannet R; Bakari M; Idbaih A; Bodemer C; Cohen-Aubart F; Haroche J; Tazi A; Boudjemaa S; Fraitag S; Emile JF; Heritier S;
    Am J Hematol; 2023 Jul; 98(7):1058-1069. PubMed ID: 37115038
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Real-time genomic profiling of histiocytoses identifies early-kinase domain BRAF alterations while improving treatment outcomes.
    Lee LH; Gasilina A; Roychoudhury J; Clark J; McCormack FX; Pressey J; Grimley MS; Lorsbach R; Ali S; Bailey M; Stephens P; Ross JS; Miller VA; Nassar NN; Kumar AR
    JCI Insight; 2017 Feb; 2(3):e89473. PubMed ID: 28194436
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association between clinicopathologic characteristics and BRAF
    Huang H; Lu T; Sun Y; Li S; Li J; Xu K; Feng RE; Xu ZJ
    Thorac Cancer; 2019 Oct; 10(10):1984-1992. PubMed ID: 31441596
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study.
    Diamond EL; Subbiah V; Lockhart AC; Blay JY; Puzanov I; Chau I; Raje NS; Wolf J; Erinjeri JP; Torrisi J; Lacouture M; Elez E; Martínez-Valle F; Durham B; Arcila ME; Ulaner G; Abdel-Wahab O; Pitcher B; Makrutzki M; Riehl T; Baselga J; Hyman DM
    JAMA Oncol; 2018 Mar; 4(3):384-388. PubMed ID: 29188284
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reproducible and sustained efficacy of targeted therapy with vemurafenib in patients with BRAF(V600E)-mutated Erdheim-Chester disease.
    Haroche J; Cohen-Aubart F; Emile JF; Maksud P; Drier A; Tolédano D; Barete S; Charlotte F; Cluzel P; Donadieu J; Benameur N; Grenier PA; Besnard S; Ory JP; Lifermann F; Idbaih A; Granel B; Graffin B; Hervier B; Arnaud L; Amoura Z
    J Clin Oncol; 2015 Feb; 33(5):411-8. PubMed ID: 25422482
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Histiocytic disorders: insights into novel biology and implications for therapy of Langerhans cell histiocytosis and Erdheim-Chester disease.
    McClain K
    Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):395-399. PubMed ID: 33275721
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.